Modeling of HIV-1 Infection: Insights to the Role of Monocytes/Macrophages, Latently Infected T4 Cells, and HAART Regimes

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Li, Qiang ^a   Lu, Furong ^b   Wang, Kaifa ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL TYPE; CENTRAL NERVOUS SYSTEM; CLINICAL OBSERVATION; DISEASE COURSE; DRUG EFFICACY; DYNAMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; LATENT PERIOD; LYMPH NODE; MACROPHAGE; MATHEMATICAL MODEL; MONOCYTE; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; QUALITATIVE ANALYSIS; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; MACROPHAGES; MODELS, THEORETICAL; MONOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84866885456     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046026     Document Type: Article

References (106)

1. Pantaleo G, Graziosi C, Fauci AS, (1993) The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328: 327-335.
2. Douek DC, Roederer M, Koup RA, (2009) Emerging concepts in the immunopathgenesis of AIDS. Annu Rev Med 60: 471-484.
3. Levy JA, (1993) Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 57: 183-289.
4. Piatek M, Saag MS, Yang LC, Clark SJ, Kappes JC, et al. (1993) High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259: 1749-1754.
5. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, et al. (1997) Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 94: 1890-1895.
6. Joly M, Pinto JM, (2006) Role of mathematical modeling on the optimal control of HIV-1 pathogenesis. AIChE J 52: 856-884.
7. CASCADE Collaboration (2000) Time from HIV-1 seroconversion to AIDS and death before widespread use of highly active antiretroviral therapy: a collaborative re-analysis. Lancet 355: 1131-1137.
8. Burton GF, Keele BF, Estes JD, Thacker TC, Gartner S, (2002) Follicular dendritic cell contributions to HIV pathogenesis. Semin Immunol 14: 275-284.
9. Wei X, Ghosh SK, Taylor ME, Johnson VA, Eimi EA, (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
10. WHO (1990) Interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemiol Rec 65: 221-224.
11. Mcmichael AJ, (2006) HIV vaccines. Annu Rev Immunol 24: 227-255.
12. Levy JA, Mackewicz CE, Barker E, (1996) Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+T cells. Immunology Today 17: 217-224.
13. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, et al. (1995) Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 1811-1815.
14. Davenport MP, Petravic J, (2010) CD8+ T Cell Control of HIV-A Known Unknown. PLoS Pathog 6 (1): e1000728 doi:10.1371/journal.ppat.1000728.
15. Heath SL, Tew JG, Szakal AK, Burton GF, (1995) Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377: 740-744.
16. Ho J, Moir S, Kulik L, Malaspina A, Donoghue ET, et al. (2007) Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J Immunol 178: 6968-6974.
17. Pantaleo G, Graziosi C, Demarest JF, Cohen OJ, Vaccarezza M, et al. (1994) Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev 140: 105-130.
18. Thacker TC, Zhou XY, Estes JD, Jiang YJ, Keele BF, et al. (2009) Follicular dendritic cells and human immunodeficiency virus type 1 transcription in CD4+ T cells. J Virol 83: 150-158.
19. Virgin HW, Wherry EJ, Ahmed R, (2009) Redefining chronic viral infection. Cell 138: 30-50.
20. Murray JM, Kaufmann G, Kelleher AD, Cooper DA, (1998) A model of primary HIV-1 infection. Math Biosci 154: 57-85.
21. Callaway DS, Perelson AS, (2002) HIV-1 infection and low steady state viral loads. Bull Math Biol 64: 29-64.
22. Kirschner DE, Webb GF, (1997) A model for treatment strategy in the chemotherapy of AIDS. Bull Math Biol 59: 95-109.
23. Perelson AS, Nelson PW, (1999) Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev 41: 3-44.
24. Nelson PW, Murray JD, Perelson AS, (2000) A model of HIV-1 pathogenesis that includes an intracellular delay. Math Biosci 163: 201-215.
25. Tuckwell HC, Corfec EL, (1998) A stochastic model for early HIV-1 population dynamics. J Theor Biol 195: 451-463.
26. Wasserstein-Robbins F, (2010) A mathematical model of HIV infection: simulating T4, T8, macrophages, antibody, and virus specific anti-HIV response in the presence of adaptation and tropism. Bull Math Biol 72: 1208-1253.
27. Wodarz D, Nowak MA, (2002) Mathematical models of HIV pathogenesis and treatment. BioEssays 24: 1178-1187.
28. Kirschner DE, (1996) Using mathematics to understand HIV immune dynamics. Notices of the American Medical Society 43: 191-202.
29. Gupta KK, Houston MD, (1993) Acute immunosuppression with HIV seroconversion. N Engl J Med 328: 288-289.
30. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, Dc Goede RE, et al. (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 66: 1354-1360.
31. Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, et al. (1991) Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 88: 9838-9842.
32. Rosenberg YJ, Janossy G, (1999) The importance of lymphocyte trafficking in regulating blood lymphocyte levels during HIV and SIV infections. Semin Immunol 11: 139-154.
33. Cameron PU, Kelly M, (2000) HIV immunopathology. HIV Management in Australasia: a guide for clinical care Chapter 2: 19-35.
34. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, et al. (1993) Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362: 359-362.
35. Kischner D, Webb GF, Cloyd M, (2000) Model of HIV-1 disease progression based on virus-induced lymph node homing and homing-induced apoptosis of CD4+ lymphocytes. J Acquir Immune Defic Syndr 24: 352-362.
36. Burkhead EG, Hawkins JM, Molinek DK, (2009) A dynamical study of a cellular automata model of the spread of HIV in a lymph node. Bull Math Biol 71: 25-74.
37. González-Scarano F, Martin-García J, (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5: 69-81.
38. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, et al. (1992) Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 42: 1736-1739.
39. Gras G, Kaul M, (2010) Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology 7: 30.
40. Caponetti G, Pantanowitz L, (2008) HIV-associated lymphadenopathy. Ear Nose Throat J 87 (7): 374-375.
41. Lieberman J, Shankar P, Manjunath N, Andersson J, (2001) Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 98: 1667-1677.
42. Ascher MS, Sheppard HW, (1988) AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 73: 165-167.
43. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM, Paul WE, (2002) CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med 8: 319-323.
44. Stefano GB, Weeks BS, Cadet P, (2000) GP120 promotes HIV survival by distracting immune surveillance. Modern Aspects of Immunobiology 1: 63-68.
45. Barsov EV, Trivett MT, Minang JT, Sun H, Ohlen C, et al. (2011) Transduction of SIV-specific TCR genes into rhesus macaque CD8+ T cells conveys the ability to suppress SIV replication. PLoS ONE 6 (8): e23703 doi:10.1371/journal.pone.0023703.
46. Althaus CL, De Boer RJ, (2011) Implications of CTL-Mediated Killing of HIV-Infected Cells during the Non-Productive Stage of Infection. PLoS ONE 6 (2): e16468 doi:10.1371/journal.pone.0016468.
47. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D, (1998) HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391: 397-401.
48. Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, et al. (1999) In vivo migration and function of transferred HIV-1 specific cytotoxic T cells. Nat Med 5: 34-41.
49. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, et al. (1999) HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 5: 518-525.
50. McNeil AC, Shupert WL, Iyasere CA, Hallahan CW, Mican JA, et al. (2001) High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci USA 98: 13878-13883.
51. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, et al. (1995) Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1: 129-134.
52. Herbein G, Van Lint C, Lovett JL, Verdin E, (1998) Distinct mechanisms trigger apoptosis in human immunodeficiency virus type-1 infected and in uninfected bystander T lymphocytes. J Virol 72: 660-670.
53. Dockrell DH, Badley AD, Villacian JS, Heppelmann CJ, Algeciras A, et al. (1998) The expression of Fas ligand by macrophages and its upregulation by human immunodeficiency virus infection. J Clin Invest 101: 2394-2405.
54. Hu QX, Barry AP, Wang ZX, Connolly SM, Peiper SC, et al. (2000) Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor itilization and AIDS pathogenesis. J Virol 74: 11858-11872.
55. Pierson T, Hoffman TL, Blankson J, Finzi D, Chadwick K, et al. (2000) Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol 74: 7824-7833.
56. Waki K, Freed EO, (2010) Macrophages and cell-cell spread of HIV-1. Viruses 2: 1603-1620.
57. Sattentau Q, (2008) Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 6: 815-826.
58. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, et al. (2010) Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 363: 257-265.
59. Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, et al. (2011) When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 154: 509-515.
60. Backer JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, et al. (2008) CD4+ count and risk of non AIDS diseases following initial treatment for HIV infection. AIDS 22: 841-848.
61. Prosperi MCF, Cozzi-Lepri A, Castagna A, Mussini C, Murri R, et al. (2010) Incidence of malignancies in HIV infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis 50: 1316-1321.
62. Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, et al. (2005) Determinants of clinical progression in antiretroviral-naïve HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med 6: 198-205.
63. Azzoni L, Chehimi J, Zhou L, Foulkes AS, June R, et al. (2007) Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells. AIDS 21: 293-305.
64. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
65. Writing Committee for the CASCADE Collaboration (2011) Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 171: 1560-1569.
66. Chun TW, Engel D, Berrey MM, Shea T, Corey L, et al. (1998) Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 95: 8869-8873.
67. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
68. Wahl SM, Greenwell-Wild T, Peng G, Hale-Donze H, Orenstein JM, (1999) Co-infection with opportunistic pathogens promotes human immunodeficiency virus type 1 infection in macrophages. J Infect Dis 179, Suppl 3: S457-S460.
69. Lawn SD, Roberts BD, Griffin GE, Folks TM, Butera ST, (2000) Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection. J Virol 74: 139-145.
70. Laforge M, Campill-Gmenez L, Monceaux V, Cumont M, Hurtrel B, et al. (2011) HIV/SIV Infection Primes Monocytes and Dendritic Cells for Apoptosis. PLoS Pathog 7: e1002087 doi:10.1371/journal.ppat.1002087.
71. Aquaro S, Caliò R, Balzarini J, Bellocchi MC, Garaci E, et al. (2002) Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 55: 209-225.
72. Mangino G, Percario ZA, Fiorucci G, Vaccari G, Acconcia F, et al. (2011) HIV-1 Nef induces proinflammatory state in macrophages through its acidic cluster domain: involvement of TNF alpha receptor associated factor 2. PLoS ONE 6 (8): e22982 doi:10.1371/journal.pone.0022982.
73. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, et al. (2005) HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 115: 3250-3255.
74. Wu Y, Yoder RAC, Kelly J, Yu D (2010) Compositions and methods for detecting and treating HIV infections. United States Patent Application. Patent No.: US20100292181A1.
75. Wang L, Robb CW, Cloyd MW, (1997) HIV induces homing of resting T lymphocytes to lymph nodes. Virology 228: 141-152.
76. Wang L, Chen JJ, Gelman BB, Konig R, Cloyd MW, (1999) Mechanism of CD4 lymphocyte depletion involves HIV's effects on resting lymphocytes: induction of lymph node homing and apoptosis upon secondary signaling through homing receptors. J Immunol 162: 268-276.
77. Kirschner DE, Perelson A (1995) A model for the immune system response to HIV: AZT treatment studies. in: Arino O, Axelrod D, Kimmel M, Langlais M (Eds.), Mathematical Population Dynamics: Analysis of Heterogeneity, vol. 1, Theory of Epidemics, Wuerz, Winnipeg, Canada 295-310.
78. AlkalizeForHealth. Lymph system in health and disease. Available: http://www.alkalizeforhealth.net/Llymphsystem.htm. Accessed 2012 Jan 17.
79. Roger W, Williams PL (1973) Angiology (Chapter 6). Gray's anatomy. illustrated by Moore REM (Thirty-fifth Edition ed.). London: Longman. pp. 588-785.
80. Loftus WK, Chow LTC, Metreweli C, (1999) Sonographic measurement of splenic length: correlation with measurement at autopsy. J Clin Ultrasound 27: 71-74.
81. Henderson JM, Heymsfield SB, Horowitz J, Kutner MH, (1981) Measurement of liver and spleen volume by computed tomography. Radiology 141: 525-527.
82. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, et al. (1999) Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 340: 1614-1622.
83. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, et al. (1997) Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278: 1447-1450.
84. Rosenberg ES, LaRosa L, Flynn T, Robbins G, Walker BD, (1999) Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Immunol Lett 66: 89-93.
85. Schaefer MR, Wonderlich ER, Roeth JF, Leonard JA, Collins KL, (2008) HIV-1 Nef Targets MHC-I and CD4 for Degradation Via a Final Common β-COP-Dependent Pathway in T Cells. PLoS Pathog 4 (8): e1000131 doi:10.1371/journal.ppat.1000131.
86. Ueno T, Motozono C, Dohki S, Mwimanzi P, Rauch S, et al. (2008) CTL-mediated selective pressure influences dynamic evolution and pathogenic functions of HIV-1 Nef. J Immunol 180: 1107-1116.
87. Cacho ED, Gallego M, López-Bernard F, Sánchez-Acedo C, Lillehoj HS, (2008) Isolation of chicken follicular dendritic cells. J Immunol Methods 334: 59-69.
88. Wei XP, Decker JM, Wang SY, Hui HX, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
89. Matloubian M, Concepcion RJ, Ahmed R, (1994) CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 68: 8056-8063.
90. Ernst JD, Stendahl O (2006) Phagocytosis of Bacteria and Bacterial Pathogenicity. New York: Cambridge University Press.
91. Van Furth R, Cohn ZA, (1968) The origin and kinetics of mononuclear phagocytes. J Exp Med 128: 415-435.
92. Janeway CA, Travers P, Walport M, Capra D (1999) Immuno Biology (4th ed). Elsevier Science Ltd/Garland Publishing, Amsterdam.
93. Tsai WP, Conley SR, Kung HF, Garrity RR, Nara PL, (1996) Preliminary in vitro growth cycle and transmission studies of HIV-1 in an autologous primary cell assay of blood-derived macrophages and peripheral blood mononuclear cells. Virology 226: 205-216.
94. Ho DD, (1996) Viral counts in HIV infection. Science 272: 1124-1125.
95. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, et al. (1999) Directly measured kinetics in circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 5: 83-89.
96. Keele BF, Tazi L, Gartner S, Liu Y, Burgon TB, et al. (2008) Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol 82: 5548-5561.
97. Kesmir C, De Boer RJ, (1999) A mathematical model on germinal center kinetics and termination. J Immunol 163: 2463-2469.
98. Grouard G, de Bouteiller O, Banchereau J, Liu YJ, (1995) Human follicular dendritic cells enhance cytokine-dependent growth and differentiation of CD40-activated B cells. J Immunol 155: 3345-3352.
99. Flexner C, (2007) HIV drug development: the next 25 years. Nat Rev Drug Discov 6: 959-966.
100. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-60.
101. King JT Jr, Justice AC, Roberts MS, Chang CCH, Fusco JS, (2003) Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making 23: 9-20.
102. Janeway CA, Travers JP, Walport M, Shlomchik MJ (2001) Immunobiology 5: The Immune System in Health and Disease, NewYork: Garland Publishing.
103. Aquaro S, Perno CF, Balestra E, Balzarini J, Cenci A, et al. (1997) Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol 62: 138-143.
104. Glenn L, André A, Alexander T, Maurizio Z, Anders S, et al. (2011) HIV-1 mutational pathways under multidrug therapy. AIDS Res Ther 8: 26.
105. Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF, et al. (1999) Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD41 T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 94: 1021-1027.
106. Deeks SG, (2007) Protease inhibitors as immunomodulatory drugs for HIV infection. Clin Pharmacol Ther 82: 248-250.